Abstract: New oral anticoagulants (NOACs) are used for the prevention of stroke in patients with atrial fibrillation and treatment of venous thromboembolism. Although the incidence of bleeding induced by NOACs is lower than that induced by vitamin K antagonists, the physicians' assessment and management of NOAC-related bleeding still remain a concern. This paper briefly reviews the research advances in the application of idarucizumab, andexanet alfa, ciraparantag, prothrombin complex concentrate (PCC), activated PCC (aPCC) and recombinant factor Ⅶa (rFⅦa) in hemostasis or reversal of anticoagulant effects of NOACs in order to provide reference for the clinical application of NOACs and treatment of related bleeding events.